Banyan Biomarkers, Abbott Ink Deal for Traumatic Brain Injury Biomarkers (360Dx)

Banyan Biomarkers, Abbott Ink Deal for Traumatic Brain Injury Biomarkers

UF startup and UF Innovate | Sid Martin Biotech alum Banyan Biomarkers announced that it has nonexclusively licensed its proprietary blood biomarkers of traumatic brain injury (TBI) to Abbott.

The biomarkers — ubiquitin carboxyl-terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury. They are the basis of San Diego-based Banyan’s Brain Trauma Indicator, which received marketing authorization from the US Food and
Drug Administration in early 2018.

Learn more about Banyan Biomarkers, Abbott Ink Deal for Traumatic Brain Injury Biomarkers.
X